Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Breast 6Gastrointestinal 4Tumor-Agnostic 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 77Nivolumab 64Ipilimumab 40Specimen Handling 33Magnetic Resonance Spectroscopy 27Cyclophosphamide 26Biopsy 20cemiplimab 16fludarabine 14Radiosurgery 14relatlimab 13CTLA-4 Antigen 13binimetinib 12Opdualag 12trametinib 11fludarabine phosphate 11avelumab 9Immunoglobulin G 9Blood Specimen Collection 9lifileucel 8dabrafenib 8atezolizumab 8Radiotherapy 8Disulfides 8encorafenib 7aldesleukin 7X-Rays 7Paclitaxel 7Standard of Care 6Interleukin-2 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
patritumab deruxtecan × Dermatologic × 90 days × Clear all
NCT06172478 2026-05-15

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

Phase 2 Recruiting
740 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡